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Abstract
Most triple-negative breast cancers (TNBCs) exhibit gene expression patterns associated with epithelial-to-
mesenchymal transition (EMT), a feature that correlates with a propensity for metastatic spread. Overexpression
of the EMT regulator Slug is detected in basal and mesenchymal-type TNBCs and is associated with reduced E-
cadherin expression and aggressive disease. The effects of Slug depend, in part, on the interaction of its N-
terminal SNAG repressor domain with the chromatin-modifying protein lysine demethylase 1 (LSD1); thus, we
investigated whether tranylcypromine [also known as trans-2-phenylcyclopropylamine hydrochloride (PCPA) or
Parnate], an inhibitor of LSD1 that blocks its interaction with Slug, suppresses the migration, invasion, and
metastatic spread of TNBC cell lines. We show here that PCPA treatment induces the expression of E-cadherin
and other epithelial markers and markedly suppresses migration and invasion of TNBC cell lines MDA-MB-231 and
BT-549. These effects were phenocopied by Slug or LSD1 silencing. In two models of orthotopic breast cancer,
PCPA treatment reduced local tumor growth and the number of lung metastases. In mice injected directly in the
blood circulation with MDA-MB-231 cells, PCPA treatment or Slug silencing markedly inhibited bone metastases
but had no effect on lung infiltration. Thus, blocking Slug activity may suppress the metastatic spread of TNBC
and, perhaps, specifically inhibit homing/colonization to the bone.
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Introduction
Treatment of breast cancer has substantially improved over the past
30 years due, in large part, to the development of more effective
combination chemotherapy protocols, endocrine therapies, and
human epidermal growth factor receptor 2–targeted therapies
[1–4]. However, progress of patients with triple-negative breast
cancer (TNBC), which are estrogen receptor–, progesterone
receptor–, and human epidermal growth factor receptor 2–negative
and represent 10% to 15% of the total, has been more limited because
they cannot be treated with endocrine or targeted therapies. Although
TNBC is histopathologically heterogeneous, the vast majority are
high-grade invasive ductal carcinomas characterized by marked
degrees of nuclear pleomorphism, lack of tubule formation, high
number of mitotic cells, and high frequency of p53 mutations [5,6].
Microarray-based analysis of TNBCs has identified six reproducible
gene expression subtypes, two of which, the mesenchymal-like and the
mesenchymal stem–like, show enrichment for gene expression
patterns associated with epithelial-to-mesenchymal transition
(EMT) [7]. Such enrichment correlates with a propensity of TNBC
cells to disseminate as indicated by increased expression of EMT
markers in breast cancer circulating tumor cells (CTCs) [8]. The EMT
is a process through which tumor cells lose homotypic adhesion,
change morphology, and acquire migratory and invasive capacity
[9,10]. EMT is thought to contribute to tumor progression, and
aberrant expression of EMT regulator/inducers in cancer cells
correlates with tumor aggressiveness and poor clinical outcomes
[11]. Transcriptional repression of E-cadherin expression is a key
event during EMT. The human E-cadherin promoter contains E-
box elements that are required for regulation of its transcription
[12]. The zinc-finger transcription factors (TFs) Snail [13], Slug
[14], Zeb1 [15], and Zeb2 [16] can bind directly to these E-boxes
and repress E-cadherin transcription. Slug contributes to invasion
in many tumor types [17–20] and can cooperate with Twist or Sox9
in promoting invasion and metastasis [21,22]. Overexpression of
Slug is detected in many tumors [23] including the basal and
mesenchymal-type TNBCs [7,24,25] and is associated with
reduced E-cadherin expression, high histologic grade, lymph node
metastasis, post-operative relapse, and shorter patients’ survival
[26–28]. Moreover, Slug represses the expression of E-cadherin and
of the cell-cell junction protein plakoglobin in TNBC cells [15,29]
and its silencing suppresses the invasion of breast cancer cells [30].
Because Slug-regulated transcription repression depends, in part,
on the interaction of its N-terminal SNAG repressor domain with
chromatin-modifying proteins such as lysine demethylase 1 (LSD1)
[31,32], inhibitors of this interaction may suppress the motility and
invasion of TNBC cells. A previous study from our laboratories has
shown that treatment with tranylcypromine [also known as trans-2-
phenylcyclopropylamine hydrochloride (PCPA) or Parnate], an Food
and Drug Administration-approved monoamine oxidase (MAO)/
LSD1 enzymatic inhibitor [33], or TAT-SNAG, a cell permeable
peptide that includes the highly conserved SNAG domain of Slug,
blocks Slug-dependent repression of the E-cadherin promoter,
suppresses the expression of morphologic and molecular markers of
EMT, and inhibits the motility and invasion of tumor cells of
different histologic and genetic backgrounds [34].
In this study, we extended these findings to investigate the effects
of PCPA and the requirement of Slug or LSD1 expression for the
migration, invasion, and EMT marker expression of TNBC cell lines
in vitro and for metastatic spread in mouse models of TNBC.
We show here that TNBC cell lines MDA-MB-231 and BT-549
are highly dependent on Slug/LSD1 activity for their migration and
invasion and that treatment with PCPA has anti-metastatic effects in
orthotopic models of breast cancer and in immunodeficient mice
injected intracardiacally with TNBC MDA-MB-231 cells.
Materials and Methods
Plasmids and Antibodies
TNBC cell lines were lentivirally transduced with the following
plasmids: pLKO-SCR-sh and pLKO-Slug-sh [34] and pLKO-Twist2-
sh and pGIPZ-LSD1-sh-H6 (purchased from Open Biosystems,
Lafayette, CO).
Slug, LSD1, and anti–β-actin expression in transduced cell lines
was detected by anti-Slug (Abgent, San Diego, CA; #AP2053a), anti-
LSD1 (Abcam, Cambridge, UK; #ab17721), and anti–β-actin (Santa
Cruz Biotechnology, Santa Cruz, CA; #sc-47778) antibodies.
Cell Lines and Treatments
Triple-negative mesenchymal-like human breast cancer MDA-MB-
231 and BT-549 [7] and 4T1 (murine animal model for stage IV
human breast cancer) cell lines were cultured in Dulbecco's modified
Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented
with 10% heat-inactivated FBS, 100 units/ml penicillin, 0.1 mg/ml
streptomycin, and 2 mM L-glutamine at 37 °C and 5%CO2. Cell lines
were obtained from American Type Culture Collection (ATCC,
Manassas, VA) and characterized by DNA fingerprinting and isozyme
detection. For in vivo experiments, cells were engineered to stably
express enhanced green fluorescent protein (copGFP) using a lentiviral
vector (pCDH-CMV-MCS-EF1-copGFP, SBI). Cells were treated
with 100 μM PCPA, a non-selective MAO-A/B/LSD1 inhibitor. All
lines were tested for mycoplasma contamination (PCR Mycoplasma
Detection Set; Takara Bio Inc, Otsu, Shiga, Japan) every 3 months.
Proliferation Assay
Cell proliferation assay was performed using CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega,Madison,Wisconsin).
Briefly, 5000 cells were seeded in 96-well flat bottom culture plates in
100 μl of culture medium. After 24, 48, 72, and 96 hours, 20 μl of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium solutionwas added to eachwell and plates were
incubated for 3 hours in a humidified 5% CO2 atmosphere.
Absorbance at 492 nm was recorded using a 96-well plate reader.
Proliferation of MDA-MB-231 and BT-549 cells was also measured by
trypan blue exclusion. Each treatment was performed in triplicate, and
the experiment was repeated at least twice.
Migration and Invasion Assay
For wound-healing assays, cells were plated to confluence onto a
six-well plate and the cell surface was scratched using a pipette tip.
Then, cells were treated with PCPA (100-500 μM), allowed to
repopulate the scratched area for 1 to 3 days, and photographed
using a digital camera mounted on an inverted microscope
(magnification, ×5). Accurate wound measurements were taken at
0 and 72 hours to calculate the migration rate according to the
equation: %wound healing = [(wound length at 0 hour) − (wound
length at 72 hours)]/(wound length at 0 hour) × 100. Experiments
were performed twice independently.
For invasion assays, cells were plated (105 cells per chamber) onto
BD BioCoat Matrigel invasion chambers (BD Biosciences, San Josè,
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CA). In the upper chamber, the medium was supplemented with 2%
heat-inactivated FBS. In the lower chamber, 20% FBS was used as a
chemoattractant. PCPA was added in the upper chamber. After 24
hours, the medium was removed and the chambers were washed twice
with phosphate-buffered saline (PBS); non-invading cells were
removed from the upper surface of the membrane by scrubbing
with a cotton-tipped swab; invading cells were fixed with 3.7%
formaldehyde in PBS for 2 minutes, washed twice with PBS,
permeabilized with methanol for 20 minutes, washed twice with PBS,
stained with 0.05% crystal violet for 15 minutes, and washed twice
with PBS. Ten fields for each chamber were photographed using a
digital camera mounted on an inverted microscope (magnification,
×10), and invading cells were counted in each field. Experiments were
carried out in duplicate and repeated twice.
Real-Time Quantitative Polymerase Chain Reaction Analyses
For real-time quantitative polymerase chain reaction (qPCR), total
RNA was isolated from PCPA-treated cells using the RNeasy Mini
Kit (Qiagen, Venlo, Netherlands). After digestion with RNase-free
DNase (Roche Applied Science, Penzberg, Germany), RNA (4 μg)
was reverse-transcribed using SuperScript III Reverse Transcriptase
Kit (Invitrogen, Carlsbad, CA), and first-strand cDNA used as a PCR
template. Reactions were done in triplicate, and RNA was extracted
from two separate experiments.
Primer pairs of analyzed genes (desmoplakin: FW 5′-
gctaaacgccgccaggat-3′, RV 5′-ccgcatgactgtgttggaat-3′; occludin: FW 5′-
gccggttcctgaagtggtt-3′, RV 5′-cgaggctgcctgaagtcatc-3′; E-cadherin:
FW 5′-ccgctggcgtctgtaggaagg-3′, RV 5′-ggctctttgaccaccgctctcc-
3′; N-cadherin: FW 5′-ctgtgggaatccgacgaatgg-3′, RV 5′-
gtcattgtcagccgctttaagg-3′; vimentin: FW 5′-ccagccgcagcctctacg-3′,
RV 5 ′ -gcgagaagtccaccgagtcc -3 ′ ; p lakog lobin : FW 5 ′ -
aaggtgctatccgtgtgtcc-3′, RV 5′-gttgttgcatgtcaggttgg-3′; huHPRT:
FW 5′-agactttgctttccttggtcagg-3′, RV 5′-gtctggcttatatccaacacttcg-
3′; huTwist: FW 5′-gtcctccagagcgacgag-3′, RV 5′-agaccgagaaggcgtagc-
3′; ZEB1: FW 5′-actcagcctcctccactc-3′, RV 5′-acaaattgccatctccagt-3′;
ZEB2: FW 5′-ggagcaggtaatcgcaagt-3′, RV 5′-cgcaggtgttctttcagatg-3′;
huSnail: FW 5′-cccaatcggaagcctaa-3′, RV 5′-cctttcccactgtcctcat-
3′; MusM desmoplakin: FW 5′-gcaacaagcccattatcc-3′, RV 5′-
gcaagaaaggtccacagc-3′; MusM occludin: 5′-atccacctatcacttcaga-3′,
RV 5′-taatctcccaccatcctc 3′; MusM E-cadherin: FW 5′-
gtctcctcatggctttgc-3′, RV 5′-ctttagatgccgcttcac-3′; MusM N-cadherin:
FW 5′-gcctatgaaggaaccacatga-3′, RV 5′-ctgtatctcagggaaaggt-3′;
MusM vimentin: FW 5′-tgtgaggtggagcgggac-3′, RV 5′-acatcgatctgga-
catgctg-3′; MusMSnail: FW 5′-ccactgcaaccgtgcttt-3′, RV 5′-
cttggtgcttgtggagcaa-3′; MusMTwist: FW: 5′-gccaggtacatcgacttcc-3′,
RV 5′-cagcttgccatcttggagt-3′; MusM glyceraldehyde-3-phosphate dehy-
drogenase: FW 5′-gttgtctcctgcgacttca-3′, RV 5′-ggtggtccagggtttctta-
3′) were designed using Beacon Design software. Real-time qPCR
was performed using GoTaq qPCR Master Mix (Promega) on a
MyIQ thermocycler (Bio-Rad, Hercules, CA) and quantified using
MyIQ software (Bio-Rad) that analyzes the Ct value of real-time
PCR data with the ΔΔCt method for fold induction and ΔCt
method for normalized expression. HPRT, a housekeeping gene
with constant expression, was used to normalize input cDNA.
In Vivo 4T1 Orthotopic Breast Cancer Model
BALB/c mice were inoculated orthotopically in the mammary fat
pad with 104 4T1 cells per mouse. Mice (18 per group) were treated
daily with PBS or with PCPA [10 mg/kg, intraperitoneally (i.p.), 5
days a week] for 28 days. Primary tumor growth was monitored once
a week with a caliper, and the volume was then calculated using the
formula d2 × D/2, where d and D are the short and the long
diameters, respectively. For evaluation of lung micrometastases,
clonogenic assays were performed on day 28: lungs were removed
from each mouse, minced, digested in 5 ml of an enzyme mix
containing 1× Hank's balanced salt solution (Lonza, Basel,
Switzerland), 1 mg/ml collagenase type IV (Worthington, Lakewood,
NJ), and 6 U/ml elastase (Roche), and incubated for 75 minutes at
4°C on a platform rocker. After incubation, samples were filtered
through and plated at different dilutions (1:2, 1:10, and 1:100)
onto 10-cm tissue culture dishes in DMEM–10% FBS containing 10
μg/ml thioguanine (Sigma, Saint Louis, MO) for clonogenic growth.
After 14 days of incubation at 37°C, tumor cells, which are
thioguanine-resistant, formed individual colonies representing micro-
metastases that were fixed with methanol and stained with Giemsa
(Sigma). Lung metastases were also evaluated on formalin-fixed
paraffin-embedded sections stained by hematoxylin-eosin, by two
operators, blindly.
In Vivo MDA-MB-231 Orthotopic Breast Cancer Model
Immunodeficient NOD/SCID/IL-2Rγnull (NSG) mice (12 per
group) were inoculated with 2.5 × 106 MDA-MB-231-GFP cells in the
mammary fat pad and treated daily with vehicle (PBS) or with PCPA
(10 mg/kg, i.p., 5 days a week) for 9 weeks. Growth of primary tumors
was evaluated every 5 days with a caliper, and the average weight at the
end of the experiments was also determined. To evaluate metastatic
spread to the lungs, at the end of treatment, lungs were fixed in
paraformaldehyde, embedded in paraffin, and stained with hematox-
ylin-eosin. Tissue slices were evaluated blindly by a pathologist and
scored formetastatic infiltration (+1 = 0-15% infiltration; +2 = 15-30%
infiltration; +3 = 30-60% infiltration; +4 = N60% infiltration). To
evaluate lung infiltration by GFP positivity, the right superior lung lobe
was dissociated by collagenase I to a single-cell suspension and analyzed
by flow cytometry. Briefly, right superior lung lobe was excised and
washed twice with PBS; 10 mg of lung was minced into pieces,
resuspended in 1ml of collagenase I solution [10ml of PBS added to 20
mg of collagenase type I (Roche), 0.1 g of BSA, 10μl of 1MCaCl2, and
10 μl of 1 MMgCl2], and incubated at 37°C for 1 hour rocking. A cell
strainer was used to divide dissociated cells from undigested tissue; then,
cells were spun down, washed twice with PBS, and resuspended in
appropriate medium for flow cytometry analyses.
In vivo Model of Hematogenous Metastatic Dissemination
Five-week-old female immunocompromisedmice (CB17-SCRF)were
obtained from Taconic (Germantown, NY) and housed in a germ-free
barrier. At 6 weeks of age, animals were anesthetized with 100 mg/kg
ketamine and 20 mg/kg xylazine administered by i.p. route and
successively inoculated in the left ventricle of the heart with MDA-MB-
231 cells [25 × 104 in 100 μl of serum-free DMEM/F12 (Invitrogen)].
Cell inoculation was performed using a 30-gauge needle connected to a 1-
ml syringe. The delivery of the cell suspension in the systemic blood
circulation was validated by the co-injection of blue fluorescent 10-μm
polystyrene beads (Invitrogen, Molecular Probes). Mice were left
untreated or treated with PCPA (10 mg/kg, i.p.; 24 hours before cell
inoculation and at days 0, 1, and 2 post-cell injection). Organs were
harvested and prepared as described below, and tissue sections were
inspected blindly for single cancer cells and tumor foci. The homogeneous
and numerically consistent distribution of the beads in adrenal glands and
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lungs collected at necropsy and inspected by fluorescence microscopy
was used as discrimination criteria for the inclusion of animals in the
studies. Additional details concerning the intracardiac inoculation of
cancer cells used here were previously reported [35–37]. All experiments
were conducted in accordance with National Institutes of Health
guidelines for the humane use of animals. All protocols were approved
by theDrexel University College ofMedicine Institutional Animal Care
and Use Committee.
Tissue Processing
Bones and soft-tissue organs were collected and fixed in 4%
paraformaldehyde solution (Electron Microscopy Sciences, Hatfield,
PA) for 24 hours and then transferred into fresh formaldehyde for an
additional 24 hours. Soft tissues were then placed either in 30% sucrose
for cryoprotection or 1% paraformaldehyde for long-term storage.
Bones were decalcified in 0.5MEDTA (Fisher Scientific, Leicestershire,
United Kingdom) for 7 days followed by incubation in 30% sucrose.
Tissues were maintained at 4°C for all the steps mentioned above and
frozen in OCT medium (Sakura Finetek, Torrance, CA) by placement
over dry ice–chilled 2-methylbutane. Serial sections of 80-μm thickness
were obtained using a Microm HM550 cryostat. Femur and tibia in
each knee joint were cut entirely through, resulting in approximately 32
sections per specimen available for analysis. For the analysis of lungs,
three representative sections per organ were analyzed and five randomly
selected microscopic fields (×10) per section were inspected for single
cancer cells and tumor foci.
Fluorescence Microscopy and Morphometric Analysis of Metastases
Fluorescent images of skeletal metastases were acquired using a
Zeiss AX70 microscope (Carl Zeiss, Oberkochen, Germany)
connected to a Nuance Multispectral Imaging System (CRI, Guelph,
Ontario). Digital images were analyzed and processed with the
Nuance Software (v. 2.4). Microscope and software calibration for
size measurement was performed using a TS-M2 stage micrometer
(Oplenic Optronics, Hangzhou, China).
Immunohistochemistry on Frozen Sections
Tumor fragments were embedded in OCT compound, snap frozen,
and stored at −80°C. Slides were fixed in acetone and air dried, rinsed in
MeOH/3% H2O2 to block endogenous peroxidase activity, washed in
PBS, and blocked in 10% fetal calf serum. Slides were covered with the
primary Ab (rat anti-mouse E-cadherin; Calbiochem, SanDiego, CA) for
1 hour and washed three times in PBS, followed by incubation with the
secondary antibody (HRP-conjugated) andHRP-conjugated streptavidin
(Sigma). Reactivity was revealed with 3,3′-diaminobenzidine. Sections
were counterstained with Mayer's hematoxylin, dehydrated in graded
alcohol (70%, 95%, and 100% ethanol), and mounted in BDH
mounting medium (Merck Eurolabs, VWR, West Chester, PA).
Statistical Analysis
Data (means ± SD, two or three experiments) were analyzed
for statistical significance by unpaired, two-tailed Student’s t test.
P values b .05 were considered statistically significant.
Results
In Vitro Effects of PCPA or Slug/LSD1 Silencing on Migration
and Invasion of TNBC Cells
In a recent study, we showed that blocking the interaction of
Slug with LSD1 by treatment with PCPA inhibited the migration and
invasion of tumor cell lines of different histologic and genetic
backgrounds [34]. Moreover, the effects of PCPA were phenocopied
by RNAi-dependent Slug or LSD1 down-regulation [34]. Since
expression of Slug appears to be important for the invasive properties
of breast cancer cells [25,30], we assessed the effects of PCPA or Slug/
LSD1 silencing for migration, invasion, and EMT marker expression
of TNBC MDA-MB-231 and BT-549 cell lines. As shown in
Figure 1, A and B, wound-healing assays revealed that treatment with
PCPA markedly inhibited migration of MDA-MB-231 cells; likewise,
PCPA-treated MDA-MB-231 cells were less invasive than the
untreated counterpart, as indicated by the marked decrease in the
number of cells migrating from the upper to the lower chamber
through a Matrigel layer (Figure 1D). Of interest, PCPA-dependent
inhibition of MDA-MB-231 cell migration or invasion was not due
to suppression of cell proliferation because growth rates of untreated
and PCPA-treated cells are undistinguishable (Figure 1C ). The
inhibitory effects of PCPAon invasion andmigration ofMDA-MB-231
cells correlated with changes in the expression of epithelial and
mesenchymal markers detected by real-time PCR (Figure 1E );
expression of E-cadherin and plakoglobin that is directly repressed by
Slug [15,29] was enhanced in PCPA-treated cells and similar increases
were noted for occludin and desmoplakin. By contrast, expression of the
mesenchymal marker N-cadherin was decreased, whereas there were no
changes in the levels of vimentin. Of interest, treatment with PCPA also
induced changes in the expression of other EMT regulators: expression
of Twist was markedly decreased, whereas levels of Snail were increased;
no significant changes in Zeb1 or Zeb2 expression were noted
(Figure 2A). The changes in E-cadherin and N-cadherin expression in
PCPA-treated MDA-MB-231 cells were confirmed by Western blot
analysis (Supplementary Figure 1).
The effect of PCPA on Slug/Snail-regulated gene expression
programs is thought to depend, at least in part, on its ability to disrupt
the interaction between the N-terminal SNAG repressor domain of
Slug/Snail and the histone demethylase LSD1 protein that is critical
for Slug/Snail-dependent transcription repression [31,38]. Thus, the
effects of PCPA should be phenocopied by Slug or LSD1 silencing.
To test this hypothesis, we generated Slug- or LSD1-silenced
MDA-MB-231 cells and assessed their migration, invasion, and EMT
marker expression profile in comparison to the scramble-transduced
counterpart. Indeed, Slug or LSD1 down-regulation (Figure 3A)
phenocopied the effects of PCPA by inhibiting migration of MDA-
MB-231 cells in wound-healing assays (Figure 3, C and D) and
suppressing their invasion when seeded onto Matrigel-coated Boyden
chambers (Figure 3E ). Like PCPA-treated cells, Slug- or LSD1-
silenced MDA-MB-231 cells showed a significant increase in the
expression of E-cadherin, occludin, and desmoplakin and a decrease
in N-cadherin levels (Figure 3F ); by contrast, expression of vimentin
did not change in Slug- or LSD1-silenced cells (Figure 3F ). Like
PCPA treatment, Slug silencing led to a marked decrease in the
expression of Twist and to increased Snail expression, whereas levels
of Zeb1 and Zeb2 did not change (Figure 2A). The decrease in Twist
expression may explain, at least in part, the effects of Slug silencing on
migration and invasion since Twist-silenced MDA-MB-231 cells
exhibited an impairment in motility (wound-healing assay) and
invasion (Matrigel invasion assay) compared to the parental cell line
(Supplementary Figure 2). Of interest, Slug silencing appears to be
more effective than LSD1 silencing in inhibiting migration and
invasion (P = .043) of MDA-MB-231 cells and in modulating the
expression of EMT markers, especially E-cadherin (Figure 3F ). Like
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PCPA-treated cells, proliferation of Slug- or LSD1-silenced MDA-
MB-231 cells was undistinguishable from that of the scramble-
transduced counterpart (Figure 3B).
Similar experiments were carried out using the TNBC BT-549 cell
line (Supplementary Figures 3 and 4). Compared to untreated cells,
PCPA-treated BT-549 cells (Supplementary Figure 3) showed a
decrease in migration and invasion and modulation of EMT marker
expression similar to that of PCPA-treated MDA-MB-231 cells.
Likewise, Slug- or LSD1-silenced BT-549 cells also exhibited
decreased invasion and migration and changes in EMT marker
expression (Supplementary Figure 4) very similar to those observed in
Slug- or LSD1-silenced MDA-MB-231 cells.
In vivo Effects of PCPA in an Orthotopic Model of Murine
Metastatic Breast Cancer
To investigate whether treatment with PCPA has anti-metastatic
effects, initial experiments were carried out using an orthotopic model
of mouse breast cancer 4T1 cells injected in the mammary fat pad of
syngeneic mice.
First, we assessed the in vitro effects of PCPA on migration,
invasion, and EMT marker expression of 4T1 breast cancer cells. As
shown in Supplementary Figure 5, A to D, treatment with PCPA
inhibited 4T1 cell migration and invasion, but the effects were less
potent than in MDA-MB-231 and BT-549 cells (compare
Supplementary Figure 5 with Figure 1 and Supplementary Figure 2).
Figure 1. Effect of PCPA on migration, invasion, proliferation, and phenotype of TNBC MDA-MB-231 cells. Photomicrographs (A) and
migration rates (B) in wound-healing assays of PCPA-treated (48 hours) MDA-MB-231 cells. (C and D) 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide and invasion assays (expressed as percentage inhibition compared to untreated cells taken as 100) of PCPA-
treatedMDA-MB-231 cells. (E) Histograms of EMTmarker expression (mean + SD; three independent experiments) detected by real-time
qPCR in MDA-MB-231 cells treated with PCPA (12 hours). Changes in mRNA levels are all statistically significant except for vimentin.
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Likewise, treatment with PCPA induced a modest increase [detected by
semiquantitative reverse transcription (RT)–PCR] in the expression of
epithelial markers E-cadherin, occludin, and desmoplakin and a
decrease in the levels of the mesenchymal marker vimentin
(Supplementary Figure 5E). PCPA treatment did not induce changes
in Snail or Twist mRNA levels (Figure 2B).
Then, BALB/c mice (n = 36) were injected in the mammary fat pad
with 4T1 breast cancer cells (104 cells per mouse), which metastasize
spontaneously to the lungs. Twenty-four hours after tumor cell
injection, 18 mice were treated with PCPA (10 mg/kg per day for 28
consecutive days; i.p.) and 18 with vehicle (PBS) only; all mice were
sacrificed at the end of the treatment. As shown in Figure 4, PCPA-
treated mice showed a decrease in primary tumor growth statistically
significant up to 21 days (Figure 4A) and, more importantly, a
reduced number of lung metastases (Figure 4B) evaluated by
clonogenic assays of homogenized lung tissue taken at the end of
the treatment (day 28). Of interest, the diminished migratory/
invasive capacity and modulation of the EMT phenotype induced by
Figure 2. Effect of PCPA or Slug silencing on EMT-regulator expression in breast cancer lines. Histograms (mean+ SD; three
independent experiments) show EMT-regulator expression in PCPA-treated (24 hours) or Slug-silencedMDA-MB-231 and in PCPA-treated
4T1 cell lines detected by real-time PCR. Asterisk denotes statistically significant changes in expression compared to controls.
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PCPA treatment in vitro correlated with increased E-cadherin
expression in primary tumors (Figure 4, C and D). A decrease in
metastases was also observed on evaluation of hematoxylin-eosin–
stained lung sections from six untreated and six PCPA-treated mice
(Figure 4E ); moreover, the size of the lesions was markedly reduced in
PCPA-treated mice compared to the untreated controls (Figure 4F ).
In Vivo Effects of PCPA in NSG Mice Injected Orthotopically
with the TNBC MDA-MB-231 Cell Line
To assess the in vivo effects of PCPA in human TNBC cells, NSG
mice were injected in the mammary fat pad with GFP-positive MDA-
MB-231 cells and, 2 days later, treated with PCPA (10 mg/kg, i.p.; 5
days per week for 6 weeks) or with vehicle only. Tumor volume was
measured every 5 days, and mice were sacrificed when tumor size of
control mice was 1.8 to 2.0 cm3. Then, we determined the weight of
local tumors and lungs and examined the infiltration of MDA-MB-
231 cells in the lungs by detection of GFP-positive cells and by
morphologic examination of tissue sections. Compared to controls,
treatment with PCPA induced a statistically significant decrease in
tumor volume, tumor and lung weight, and lung infiltration (GFP
positivity and Giemsa staining; Figure 5).
Effects of PCPA Treatment or Slug Silencing on Homing and
Colonization of MDA-MB-231 Cells in Bone and Lungs
These experiments were undertaken to determine whether PCPA
treatment impairs the lodging of human breast cancer cells to the
skeleton from the hematogenous circulation. To this end, stably
fluorescent MDA-MB-231 cells were converted into CTCs by direct
delivery into the left heart ventricle of immunocompromised mice.
Seventy-two hours after inoculation, animals were sacrificed and
evaluated for disseminated tumor cells (DTCs) in the distal femur and
proximal tibia, which were inspected throughout the entire bone
thickness by obtaining serial frozen sections. Compared to control
animals, mice treated with PCPA (10 mg/kg, i.p.; 24 hours before cell
inoculation and at days 0,1, and 2 post-cell injection) showed a
dramatic decrease in the number of DTCs. Similar results were
obtained by inoculating Slug-silenced MDA-MB-231 cells
(Figure 6A). Interestingly, a reduction in DTCs was not observed
on inspection of the lungs in the same animals (Figure 6B ).
To ascertain the long-term effects of the observed DTC reduction
on the growth of skeletal tumors, additional mice inoculated with
MDA-MB-231 cells and treated as described above were allowed to
progress for 15 days post-inoculation. When these mice were
sacrificed and inspected for fluorescent tumor foci in the knee
joint, control animals showed large tumors encompassing more than
80% of tibiae’s and femora’s tissue sections, whereas PCPA-treated
mice displayed an involvement of only approximately 50%. Even
more striking were the results obtained with Slug-silenced MDA-MB-
231 cells; on intracardiac inoculation, these cells generated tumors
involving less than 10% of bone sections (Figure 6C ). A
quantification of the overall bone involvement in each experimental
group confirmed the significant reduction in skeletal tumor growth of
either PCPA-treated or Slug-silenced MDA-MB-231 human breast
cancer cells (Figure 6, D and E ).
Figure 3. Effect of Slug or LSD1 silencing on migration, invasion, proliferation, and phenotype of TNBCMDA-MB-231 cells. (A) Western blot
shows Slug or LSD1 expression in scramble or Slug/LSD1-silencedMDA-MB-231 cells. (B) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay of control or Slug/LDS1-silencedMDA-MB-231 cells. (C) Photomicrographs showwound-healing assay on Slug/LSD1-silenced
MDA-MB-231 cells. (D)Histograms represent accuratemeasurements ofmigration at 0 and48hours of control and Slug/LSD1-silencedMDA-
MB-231 cells. (E) Invasion assay: histograms show invasion (expressed as percentage inhibition compared to scramble shRNA-transduced
cells taken as 100) of Slug/LSD1-silenced cells. (F) Histograms of EMT marker expression (mean + SD; three independent experiments)
detectedbyRT-qPCR in Slug/LSD1-silencedMDA-MB-231 cells. Changes in geneexpression are all statistically significant except for vimentin.
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Discussion
Recent studies have shown that the transcription repression function
of Snail/Slug that is essential for the EMT-promoting effects
depends, in part, on the interaction of the N-terminal SNAG
domain of Snail/Slug with the amine oxidase domain of the
chromatin-modifying protein LSD1 [31,38]. On the basis of this
finding, we showed that disrupting the interaction between Slug and
LSD1 by treatment with theMAO/LSD1 inhibitor PCPA suppresses
the migration and invasion of cancer cells of different origin and
genetic background [34].
In this study, PCPA treatment or Slug silencing were used to
investigate the requirement of Slug for the migration, invasion, and
metastatic spread of TNBC cell lines. We selected this model because
TNBC has a high propensity to metastasize and shows high
expression of Snail and Slug, and EMT markers are readily detectable
in breast cancer CTCs [5,7,8,24,25].
We show here that PCPA treatment or Slug/LSD1 silencing
suppressed the migration and invasion of TNBC MDA-MB-231 and
BT-549 cells without inhibiting their proliferation. Moreover, PCPA
treatment or Slug/LSD1 silencing induced an increase in the levels of
E-cadherin and other epithelial markers whose expression is typically
downregulated during the EMT process [14]. By contrast, expression
of the mesenchymal marker N-cadherin was downregulated in both
TNBC cell lines, whereas levels of vimentin were only downregulated
in BT-549 cells. Slug silencing appears to inhibit migration and
invasion of MDA-MB-231 cells and to induce E-cadherin expression
more effectively than LSD1 silencing (Figure 3); this probably reflects
the ability of Slug to function, in part, through LSD1-independent
transcription repressor complexes involving distinct protein domains
[39]. Of interest, PCPA treatment or Slug silencing also affected the
expression of the EMT regulator Twist and Snail; in particular, Twist
expression was markedly decreased, whereas levels of Snail were
increased (Figure 2A).The decreased expression of Twist appears to be
biologically relevant as Twist-silenced MDA-MB-231 cells exhibit
impaired motility and invasion compared to parental cells (Supple-
mentary Figure 2).
The increase in Snail expression may depend on PCPA- or Slug
silencing–induced reversal of Slug transcription repression since a
functional E-box is present in the Snail promoter [40]; the decrease in
the levels of Twist may be due to indirect mechanisms through
inhibition of a TF positively regulating Twist expression. These
results suggest that the decrease in expression/activity of Slug and
Figure 3. (continued).
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Twist is not compensated by maintaining basal levels of Zeb1 and
Zeb2 and even increasing Snail expression. Incidentally, the increase
in expression of Snail would be less important for the effect of PCPA
that functions by blocking the Snail/Slug-LSD1 interaction. In
aggregate, these data strongly suggest that Slug and Twist have a
predominant role among the EMT regulators in controlling the
EMT process in the TNBC cell lines used here, consistent with the
high expression of Slug and Twist in the highly aggressive TNBC
subtypes [7,25].
Snail expression appears also to be required for in vitro invasion
and lymph node metastasis of MDA-MB-231 cells [41]; however, the
cells failed to form lung metastases and it is unknown if Twist
expression was also affected by Snail silencing [41].
The in vivo effects of PCPA treatment were investigated in
syngeneic or immunodeficient mice orthotopically injected with
murine 4T1 or human MDA-MB-231 breast cancer cells, respec-
tively, or after intracardiac injection of MDA-MB-231 cells in
immunodeficient mice.
Figure 4. In vivo effects of PCPA in the 4T1 mouse breast cancer model. (A) Primary tumor volume and (B) Lung metastases (counted by
clonogenic assay; see Materials and Methods section for details) in untreated or PCPA-treated BALB/c mice orthotopically injected
with 4T1 breast cancer cells. Graphs show pooled data of two (A) or three (B) experiments each performed with six mice per group.
(C) E-cadherin expression in primary tumor samples. Five random fields for each sample (five tumors per group) were evaluated blindly
under a bright-field microscope by two operators and a score of 1 to 3 was assigned. Histogram shows mean + SD of E-cadherin
expression in the control and PCPA-treated groups. (D) Representative immunihistochemistry images of E-cadherin staining. (E) Number
of lung metastases detected by hematoxylin-eosin staining of formalin-fixed paraffin-embedded sections. (F) Representative images of
lung sections from untreated and PCPA-treated mice bearing 4T1 tumors; ×40 and ×100 enlargements are shown. Arrows indicate two
small metastases inside or in close proximity to the vessels.
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In each of these models, PCPA treatment had anti-metastatic
effects as indicated by decreased lung infiltration in mice
orthotopically injected in the mammary fat pad and reduced
bone localization in mice inoculated with MDA-MB-231 cells in
the left ventricle.
In the 4T1 model, treatment with PCPA had somewhat modest
effects likely because Slug plays a less important role than Twist in
controlling the EMT in these cells [20,42] and Twist expression was
not decreased after PCPA treatment (Figure 2B).
In the orthotopic model with MDA-MB-231 cells injected in
immunodeficient NSG mice, treatment with PCPA markedly sup-
pressed colonization of tumor cells to the lungs as indicated by a
significant decrease in lung weight and tumor cell infiltration determined
by GFP positivity and morphology (Figure 4). Of interest, local tumors
of PCPA-treated mice were smaller and had a more compact and
rounded appearance than those of the untreated counterpart; this may
reflect constraints on local growth caused by an increase in cell adhesion
and a decrease in local infiltration, although in vivo effects of PCPA on
MDA-MB-231 cell proliferation and survival cannot be excluded. These
effects are in excellent correlation with the inhibition of in vitro
migration and invasion of MDA-MB-231 cells induced by PCPA
treatment and by Slug or LSD1 silencing; moreover, they also support
the concept that the metastasis-inhibitory effects of PCPA depend on
disruption of the Slug/Snail-LSD1 interaction that is essential for
transcription repression of E-cadherin expression [31,34,38].
In the model of intracardiac inoculation of MDA-MB-231 cells,
PCPA treatment or Slug silencing markedly suppressed homing
and metastasis to the bone but had no effect on homing or
metastasis to the lungs. These findings are consistent with Slug/
LSD1-specific effects regulating the bone-homing abilities of
Figure 5. Effects of PCPA on tumor growth and lung metastases of GFP-positive MDA-MB231 cells orthotopically injected in NSG mice.
(A) Tumor volume. (B and C) Tumor weight and size. (D and E) Lung weight and size. (F) Lung GFP positivity. (G and H) Lung infiltration of
control or PCPA-treated samples.
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MDA-MB-231 breast cancer cells. Furthermore, the significant
reduction in the size of skeletal lesions generated by cells in which
Slug expression was continuously suppressed suggests that this TF
promotes tumor growth in the bone microenvironment.
However, the inhibition of MDA-MB-231 lung metastasis by
PCPA treatment in the orthotopic model contrasts with a lack of
effect in the intracardiac model; this suggests that inhibition of the
Slug/LSD1-regulated EMT program by PCPA treatment may
preferentially impair the intravasation step leading to a decrease in
the number of CTCs more than affecting their extravasation as
DTCs in the lung microenvironment.
In summary, this study suggests that treatment with PCPA or with
other inhibitors of Slug/LSD1-regulated EMT may serve as an
adjuvant therapy for patients with TNBC in whom the primary
tumor has been ablated by surgery or radiation. Moreover, the finding
that PCPA has tumor-inhibitory effects in the bone supports the
concept that treating existing skeletal lesions with this drug may
impair metastatic progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.10.006.
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